Retatrutide triple agonist obesity trial
study035
10.1056/NEJMoa2301972
New England Journal of Medicine
phase 2 clinical trial
Retatrutide investigated as GLP-1/GIP/glucagon receptor agonist.
Marked reductions in body weight and metabolic improvements observed.
retatrutide
fat-loss|metabolism
advanced-metabolic-stack
retatrutide-vs-tirzepatide
published